HC Wainwright Forecasts Annexon’s Q4 Earnings (NASDAQ:ANNX)

Annexon, Inc. (NASDAQ:ANNX) – Analysts at HC Wainwright reduced their Q4 2026 earnings per share estimates for shares of Annexon in a report released on Tuesday, November 10th. HC Wainwright analyst A. Ghosh now anticipates that the company will earn ($0.28) per share for the quarter, down from their previous estimate of ($0.24). HC Wainwright currently has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Annexon’s current full-year earnings is ($1.05) per share. HC Wainwright also issued estimates for Annexon’s Q1 2027 earnings at ($0.26) EPS, Q2 2027 earnings at ($0.27) EPS, Q3 2027 earnings at ($0.27) EPS, Q4 2027 earnings at ($0.19) EPS, FY2027 earnings at ($0.99) EPS, FY2028 earnings at ($0.26) EPS and FY2030 earnings at $1.61 EPS.

Several other research analysts have also commented on ANNX. Citigroup initiated coverage on shares of Annexon in a report on Tuesday, July 21st. They issued a “market underperform” rating for the company. Citizens Jmp raised Annexon from an “underperform” rating to a “market perform” rating in a report on Thursday, August 13th. Wall Street Zen downgraded Annexon from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Annexon in a research note on Thursday, October 15th. Finally, JPMorgan Chase & Co. increased their target price on Annexon from $14.00 to $15.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 30th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $15.29.

Annexon Stock Down 0.5%

Shares of NASDAQ:ANNX opened at $4.19 on Thursday. The stock has a market capitalization of $794.34 million, a price-to-earnings ratio of -4.03 and a beta of 1.43. Annexon has a 1-year low of $2.54 and a 1-year high of $7.18. The company’s fifty day moving average is $4.06 and its two-hundred day moving average is $5.13. The company has a debt-to-equity ratio of 0.35, a quick ratio of 5.53 and a current ratio of 5.79.

Annexon (NASDAQ:ANNX) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.03.

Insider Activity at Annexon

In other news, CEO Douglas Love purchased 26,065 shares of the company’s stock in a transaction on Thursday, September 24th. The shares were bought at an average price of $3.83 per share, for a total transaction of $99,828.95. Following the completion of the purchase, the chief executive officer owned 390,476 shares of the company’s stock, valued at $1,495,523.08. This trade represents a 7.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 10.31% of the company’s stock.

Hedge Funds Weigh In On Annexon

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. bought a new stake in Annexon during the 3rd quarter valued at $41,000. Sowell Financial Services LLC bought a new position in Annexon during the third quarter valued at about $57,000. Integrated Wealth Concepts LLC lifted its stake in Annexon by 32.3% during the second quarter. Integrated Wealth Concepts LLC now owns 13,537 shares of the company’s stock valued at $77,000 after purchasing an additional 3,305 shares during the last quarter. Forefront Analytics LLC bought a new stake in shares of Annexon during the 2nd quarter worth $81,000. Finally, Coastal Bridge Advisors LLC purchased a new stake in Annexon during the second quarter valued at about $97,000.

Annexon News Summary

Investors following ANNX have been watching these news items:

• Positive Sentiment: HC Wainwright raised its FY2029 EPS estimate to $0.65 from $0.58 and its FY2030 estimate to $1.61 from $1.36, suggesting improved longer-term earnings potential.
• Neutral Sentiment: HC Wainwright kept its Buy rating and $14 price target despite revising several estimates.
• Negative Sentiment: HC Wainwright cut its FY2027 EPS forecast to a loss of $0.99 per share from a loss of $0.69, and its FY2028 estimate to a loss of $0.26 from $0.16. It also lowered estimates for Q4 2026 and each quarter of 2027, pointing to greater expected losses in the near term.

Annexon Company Profile

Annexon is a clinical-stage biopharmaceutical company developing antibody-based therapies for diseases driven by the complement system, a part of the immune system involved in inflammation and tissue damage. The company focuses on the classical complement pathway, which it aims to inhibit selectively. Its investigational programs are designed for complement-related autoimmune, inflammatory and neurodegenerative conditions. These include treatments being studied for disorders affecting the nervous system and the eye.